Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2012, Article ID 614781, 6 pages
Research Article

Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation

1Division of Hepatology, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA
2Division of Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
3Division of Nephrology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA

Received 16 August 2011; Revised 5 October 2011; Accepted 17 October 2011

Academic Editor: P. Burra

Copyright © 2012 Elizabeth J. Carey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


New-onset diabetes after transplantation (NODAT) is common after liver transplant and associated with poorer outcomes. The aim of this study was to identify risk factors for NODAT in liver transplant recipients off corticosteroids. In 225 adult nondiabetic liver transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation, 17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were significant. Each 10 mg/dL increase in pretransplant FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in patients off corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.